BMY241108P57000
- 1.93
- +0.53+37.86%
Bristol-Myers Squibb Newsroom
Here's Why Bristol-Myers Squibb (NYSE:BMY) Can Manage Its Debt Responsibly
US stock mining | AI demand surges! Software giant palantir soared nearly 200% this year, "little nvidia" ALAB surged nearly 40% last night
The election topic ignites hot discussions! The media platform Reddit tracked the election night, surging over 12% overnight, closing at a new high.
Bristol Myers Squibb to Participate in Upcoming Investor Conferences
Unusual Options Activity: COIN, NXPI and Others Attract Market Bets, COIN V/OI Ratio Reaches 130.0
EST Nov 5th Morning Delivery - In the last two hours of trading, 10 options with a high V/OI ratio were detected. With the market volatile, it's crucial to stay informed on the latest options trends.
Analysts' Top Healthcare Picks: Bristol-Myers Squibb (BMY), Agios Pharma (AGIO)
Bristol-Myers Squibb: Hold Rating Maintained Amid Positive Clinical Trials and Long-term EPS Concerns
Leerink Partners Maintains Bristol-Myers Squibb(BMY.US) With Hold Rating, Raises Target Price to $55
Express News | Bristol-Myers Squibb: Opdivo in combination with cisplatin chemotherapy approved for first-line treatment of urothelial carcinoma.
Is Bristol-Myers Squibb Company (BMY) the Best Pharma Stock to Buy Right Now?
Summit Therapeutics 'Unique Investment In Oncology,' Lead Drug Candidate Shows Promise Over Keytruda And Opdivo
How Is The Market Feeling About Bristol-Myers Squibb?
Express News | Bristol-Myers Squibb Co : Leerink Partners Raises Target Price to $55 From $53
Bristol-Myers Squibb Company PFD CONV 2 Goes Ex Dividend Tomorrow
Bristol-Myers Squibb (BMY.US) announced positive Phase 3 data for a potential blockbuster therapy for the treatment of schizophrenia.
Bristol-Myers Squibb (BMY.US) announced the latest topline results of the open-label phase 3 trials EMERGENT-4 and EMERGENT-5.
Bristol Myers Squibb Expects New Schizophrenia Treatment To Boost Long-Term Growth, Analysts Remain Cautious
Unusual Options Activity: AMZN, AAPL and Others Attract Market Bets, AMZN V/OI Ratio Reaches 166.7
EST Nov 1st Afternoon Delivery - In the last two hours of trading, 10 options with a high V/OI ratio were detected. With the market volatile, it's crucial to stay informed on the latest options
Bristol-Myers Squibb Is Maintained at Market Perform by BMO Capital
Bristol-Myers Squibb Analyst Ratings
Bristol Myers Posts Long-term Phase 3 Data for Schizophrenia Drug Cobenfy
A Quick Look at Today's Ratings for Bristol-Myers Squibb(BMY.US), With a Forecast Between $36 to $60